Board summary
Key figures
44,515
Registered population
68.0% aged 18–64
13.5%
Aged 65+
ICB 14.9% · England 17.9%
31%
Ethnic minority (non-White)
17.3% Asian · England 9.6%
17.4%
In IMD quintile 1
ICB 40.7% · England 21.0%
~7,796
Core20 residents (est.)
Resident basis; registered basis ~8,156 · see page 3
4,889
Hypertension register
+9.17% in 3 yrs · England +5.60%
489
SMI register
5.2% of Manchester (LAD)'s
666
COPD register
Reviews +4.04% in 3 yrs
Forecast to 2030
5,866
Hypertension patients, 2030
+977 on today
75.5%
QRISK ≥20% on statins, 2030
+3.50pp over 3 yrs
3.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Deprivation concentrated in two PCN practices.
Core20 share spans 59.9 pp: David Medical Centre is at 60.7% and Kingsway Medical Practice at 51.6%, against 0.8% at Barlow Medical Centre.
Mental health physical checks fell over 2023-2025.
Over 2023 to 2025, psychosis alcohol recording fell 6.3 pp (England +5.4 pp), while SMI BMI (-4.1 pp) and BP (-1.8 pp) also declined.
Hypertension BP recording and control beat England.
Recent BP recording reaches 91.3% (England 90.0%) and control to target is 71.2% (England 70.3%), though crude prevalence is 10.6% (England 15.2%).
Population, age and ethnicity
A working-age population of 44,515 coexists with 31% non-White residents across four practices
Across 44,515 registered patients, 68.0% (30,290) are aged 18 to 64, compared with 68.9% in Manchester (LAD), 63.3% in NHS Greater Manchester ICB, and 62.7% in England. Patients aged 65 and over make up 13.5% (6,017), above Manchester (9.6%) but below the ICB (14.9%) and England (17.9%). Resident Census estimates show a 31% non-White population, led by 17.3% Asian / Asian British residents (Manchester 20.9%, ICB 13.6%, England 9.6%), reaching 24.9% at Kingsway Medical Practice. These Census estimates reflect usual residents rather than GP registers.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
A 17.4% PCN Core20 share masks a 59.9 pp spread between practices
The PCN Core20 share is 17.4%, below England (21.0%), NHS Greater Manchester ICB (40.7%) and Manchester (59.8%). A 0.95 pp difference against the 18.3% weighted practice share reflects differing bases. Across practices, Core20 deprivation spans 59.9 pp: David Medical Centre is at 60.7% (an estimated 4,470 patients), Kingsway Medical Practice is at 51.6% (an estimated 3,074 patients), Didsbury Medical Centre - Dr Whitaker is at 3.1%, and Barlow Medical Centre is at 0.8%. Concentrated Core20 deprivation suggests outreach could prioritise the two higher-share practices over uniform allocation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
489
SMI register
1.06% recorded prevalence
193
Learning disability register
0.42% recorded prevalence
12
Care homes, 318 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
Recorded learning disability prevalence is 0.4% (193 patients) and severe mental illness is 1.1% (489 patients), alongside 12 catchment care homes holding 318 beds. Borough-level rough sleeping (55 people in Manchester) and unpaid care (8.7%) describe the wider authority and cannot be extrapolated to GP lists. With severe mental illness prevalence at 1.1% (England 1.0%) and learning disability at 0.4% (England 0.6%), severe mental illness may represent a larger register.
Severe mental illness: physical health checks
Over 2023 to 2025, SMI checks fell: alcohol fell 6.3 pp (England +5.4 pp), BMI fell 4.1 pp (England +5.1 pp), and blood pressure fell 1.8 pp (England +4.4 pp). Blood pressure checks reached 62.9% at David Medical Centre.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,889
Hypertension register
+9.17%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
+2.92pp
BP control, under 80
≤140/90 · +2.38pp aged 80+
+977
More patients by 2030
Forecast 5,866 (12.58%)
Hypertension case-finding and control
Hypertension QOF prevalence is 10.6% (4,889 patients), compared to Manchester (10.5%), NHS Greater Manchester ICB (14.4%) and England (15.2%), with 3-year growth of +9.2% over 2023 to 2025 (England +5.6%). Blood pressure recording reaches 91.3% (England 90.0%) and overall treatment to target is 71.2% (England 70.3%). However, control among patients aged 80 and over is 79.8%, trailing England (81.2%) and the ICB (83.2%).
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 67.9% (England 63.6%). However, statin treatment for diabetes patients aged 40 and over without CVD fell 2.4% over 2023 to 2025 (England +2.1%) to 74.4%.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 67,428 | £2.20 | £1.94 | £1.86 | £148,342 |
| Cardiovascular (all), 2025 | 91,362 | £2.54 | £3.15 | £3.33 | £232,059 |
For lipid-modifying drugs in 2026, the PCN prescribed 67,428 items at £2.20 per item, compared to £1.86 in England and £1.94 in NHS Greater Manchester ICB, spending £22,926 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+16.27%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+5.23%
Asthma prevalence, PCN 3-yr % change
Asthma reviews rose +16.3% over 2023 to 2025 to 68.0%, above Manchester (67.0%), NHS Greater Manchester ICB (66.2%) and England (65.7%), yet an estimated 936 of 2,926 register patients lack a review. Youth asthma second-hand smoke recording is 74.2%, below Manchester (76.0%), the ICB (79.7%) and England (78.8%). COPD reviews stand at 67.6% across 666 register patients, below Manchester (74.5%), the ICB (76.4%) and England (76.4%). Structured respiratory recall should prioritise unreviewed asthma and COPD cohorts.
Cancer register and children's immunisation
Cancer prevalence is 3.2% (1,493 patients), compared to 2.2% in Manchester, 3.3% in NHS Greater Manchester ICB and 3.8% in England. For age-5 immunisations in Q1 2025/26, 4-in-1 booster coverage is 77.2% (below the 95.0% target by 17.8 pp) and MMR dose 2 is 85.9% (below target by 9.1 pp), with a 5.4 pp difference between first and second doses.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers (6,491 of 11,679 with known stage) in NHS Greater Manchester ICB were diagnosed at stage 1 or 2, similar to England (55.3%) but 19.4 pp below the 75.0% national ambition, needing 2,268.2 extra early-stage diagnoses across the ICB. Known-stage coverage was 70.8% (11,679 of 16,492 registered cancers); missing stage limits direct inference and reflects system pathways rather than PCN delivery. Locally, PCN breast screening coverage is 63.1% (England 69.9%) despite a +20.1% rise over 2023 to 2024, with David Medical Centre at 49.3% and Kingsway Medical Practice at 55.8%. Targeted outreach at lower-uptake practices could improve early detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Manchester University NHS Foundation Trust achieved 72.8% on the 62-day cancer standard (12.2 pp below the 85.0% standard), behind Northern Care Alliance NHS Foundation Trust (78.6%), Stockport NHS Foundation Trust (74.7%), and NHS Greater Manchester Integrated Care Board (75.7%), but above England (71.2%). On the 28-day faster diagnosis standard (target 75.0%), Manchester University reached 80.1% (ICB 79.5%, England 79.3%). In diagnostics, Manchester University recorded 14.7% waiting 6+ weeks for Computed Tomography (England 9.9%). These trust figures reflect acute provider performance.
| Pathways within standard (%) | Manchester | Stockport | Northern Care Alliance | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 83.21 | 75.20 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 97.39 | 94.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 74.67 | 78.65 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Stockport | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 11.68 | 1.41 | 5.09 | 21.40 |
| CT | 14.66 | 2.93 | 4.10 | 9.92 |
| Echocardiography | 4.91 | 17.46 | 31.48 | 28.48 |
| Colonoscopy | 4.51 | 5.53 | 40.04 | 30.83 |
| Gastroscopy | 29.35 | 5.31 | 36.48 | 29.02 |
| All 15 DM01 tests | 8.98 | 14.08 | 15.71 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In Jun 2026, 43.3% of community service contacts among Manchester borough residents were with adults aged 65 and over (42,015 of 96,995 contacts). These provisional figures describe local authority residents rather than PCN-specific activity, highlighting substantial community service delivery directed toward older residents across the borough.
Practice variation and patient experience
Practice vaccination achievement spans 84.4 percentage points alongside uneven telephone access
In 2025/26, clinical-domain QOF achievement was near-total across all practices, between 99.9% and 100.0%. However, vaccination and immunisation achievement showed an 84.4 pp spread, from 15.6% at David Medical Centre and 40.7% at Kingsway Medical Practice to 100.0% at Didsbury Medical Centre - Dr Whitaker. Personalised care adjustments peaked at 17.2% at David Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Didsbury - Dr | 111 | 3.1 | 71.2% | 85.9% | 87.5% |
| Barlow | 94 | 0.8 | 49.2% | 71.2% | 80.8% |
| Kingsway Medical | 73 | 51.6 | 59.0% | 60.2% | 77.0% |
| David | 118 | 60.7 | 67.8% | 66.5% | 76.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Physical checks fell for 489 severe mental illness patients while breast screening rose +20.1%
Widest three-year lags against England over 2023 to 2025 were in physical checks for 489 severe mental illness patients and heart failure reviews. Alcohol recording fell 6.3 pp (England +5.4 pp), BMI recording fell 4.1 pp (England +5.1 pp), and blood pressure checks fell 1.8 pp (England +4.4 pp). Functional heart failure reviews fell 2.3% (England +8.7%), despite current recording reaching 89.3% (England 78.5%). Three-year strengths included asthma reviews (+16.3% vs England +4.4%), cervical screening (+1.8% vs England -1.0%), and breast screening (+20.1% vs England +8.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Alcohol record (psychosis)
Heart failure reviews
BMI record (SMI)
BP check (SMI)
Diabetes statin (no CVD)
Asthma reviews
Breast screening (53-70)
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 12 (318 beds) | n/a | Schools (catchment) | 54 | n/a |
| Children's centres | 4 | 34 | Places of worship | 34 | 289 |
| Libraries | 2 | 16 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 6 | 68 | Primary academies | 5 | 50 |
| Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and COPD recall
An estimated 936 of 2,926 asthma patients lack an annual review (68.0% vs England 65.7%), and COPD reviews sit at 67.6% of 666 patients (England 76.4%). For discussion: the PCN could run a single-template respiratory recall and offer flexible clinic slots, starting in the highest-deprivation practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
SMI physical health check recovery
Over 2023 to 2025 across 489 SMI patients, BP checks fell 1.8 pp to 82.0% (England 83.4%, +4.4 pp), BMI fell 4.1 pp, and alcohol recording fell 6.3 pp. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Targeted screening and booster catch-up
Breast screening is 63.1% (England 69.9%; David Medical Centre 49.3%, Kingsway Medical Practice 55.8%). Age-5 4-in-1 coverage is 77.2% (below the 95.0% target by 17.8 pp) and MMR2 is 85.9% (below by 9.1 pp). Moderate effort to run.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Tailored communication outreach (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recovery (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older adult hypertension review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation catch-up (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted breast screening recall (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Practice telephone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma and COPD recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · SMI physical health check recovery (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Targeted screening and booster catch-up (p12) | Breast screening coverage: aged 53 to 70 years old · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 2 coverage at age 5 | — | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
